Prognostic value of CT characteristics in crizotinib-treated patients with advanced non-small cell lung cancer
10.3969/j.issn.1000-8179.2019.11.201
- VernacularTitle:胸部CT特征对克唑替尼治疗晚期非小细胞肺癌疗效及预后的预测价值
- Author:
Yidi WANG
1
;
Hua WANG
;
Lizhu HAN
;
Ying HAN
;
Juxiang MA
;
Zhaoxiang YE
Author Information
1. 天津医科大学肿瘤医院放射科
- Keywords:
computed tomography (CT);
non-small cell lung cancer (NSCLC);
anaplastic lymphoma kinase (ALK);
crizotinib,prognosis
- From:
Chinese Journal of Clinical Oncology
2019;46(11):568-574
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the prognostic value of chest computed tomography (CT) characteristics in crizotinib-treated pa-tients with advanced non-small cell lung cancer (NSCLC). Methods: Forty-seven patients with advanced ALK-rearranged NSCLC who re-ceived crizotinib treatment from January 2014 to March 2017 were enrolled in this retrospective study. Pre-treatment CT characteris-tics were evaluated. Patients were followed up after crizotinib treatment, and the best overall response and progression-free survival (PFS) were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1). Results: The median PFS of all patients was 10 months. There was no association between CT characteristics and response. In univariate analysis, large tumor size (P=0.009), central type (P=0.002), consolidation of surrounding lung tissue (P=0.002), pleural effusion (P=0.001), and lymphangitic carcino-matosis (P=0.019) suggested a poor prognosis. Multivariate Cox regression analysis showed that location (hazard ratio, 3.219; 95% con-fidence interval: 1.517-6.833; P=0.002) was an independent prognostic predictor. Conclusions: Pre-treatment CT characteristics are useful in predicting the PFS of crizotinib-treated patients with advanced NSCLC harboring ALK rearrangement.
